A Phase 3 interventional study of Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection in Gastric Cancer and Surgery, sponsored by Fujian Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-24.
Sponsored by Fujian Medical University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Stomach Neoplasms by Fujian Medical University — 16 open to participants now, 20 under way, 6 of them phase 3. Stomach Neoplasms · Fujian Medical University.
Among the 56 studies in Stomach Neoplasms by Fujian Medical University, this one is the 2nd largest by planned enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2023, is one of 7 in phase 3, reaches primary completion later than 14 of the 19 other live ones, and was the 41st registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →16 of the 56 studies in Stomach Neoplasms by Fujian Medical University are open now, in 1 country. Recruiting first, the newest first:
Fujian Medical University · Sites in China
Ages 18–75
Fujian Medical University · Sites in China
Ages 18–75
Fujian Medical University · Sites in China
Ages 18–75
Fujian Medical University · Sites in China
Ages 18–75
Fujian Medical University · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 702 is above the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.
Median enrollment 192 across the 32 interventional studies, 507 across the 24 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fujian Medical University is the lead sponsor of 148 studies on the registry; 52 are open to participants now.
3 of the studies in Stomach Neoplasms by Fujian Medical University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314203Phase 3Fujian Medical UniversityClinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer | 2027-08-25 |
| NCT03716089Fujian Medical UniversityComparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site | 2027-04-01 |
| NCT07356466Fujian Medical UniversityClinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Stomach Neoplasms by Fujian Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with locally advanced gastric adenocarcinoma (CT2-4a N-/+ M0) were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in 3D plus ultra high resolution laparoscopic gastrectomy with lymph node dissection for gastric cancer.
2.1 Case group Group A (Study Group 1, 234 cases): ICG near-infrared imaging tracing in 3D plus ultra high resolution laparoscopic gastrectomy with lymph node dissection; Group B (Study Group 2, 234 cases): ICG near-infrared imaging tracing in ultra high resolution laparoscopic gastrectomy with lymph node dissection; Group C (Control Group 2, 234 cases) 3D laparoscopic gastrectomy with lymph node dissection
2.2 Estimate Sample Size The three-year disease-free survival (DFS) was the main effectiveness evaluation index in this study. The study implemented a superiority test (unilateral), assuming that both the study group's three-year DFS would be better than that of control group, according to previous research results of laparoscopic surgery for locally advanced GC in which the three-year DFS was 65.2%; therefore, the 3-year DFS of the control group would be 65.2%, assuming that the 3-year DFS of the experimental group could be increased by 12% to 77.2%. With an inspection level 0.0125 (unilateral) and an inspection efficiency of 0.8 and using PASS 11 log-rank tests (Lakatos) [Proportion surviving] the calculated sample size was N=211; namely, each group needed 211 people, considering cases of possible exclusion and loss to follow-up (10% drop out rate). The final sample size for each group was 234 cases, for a total of 702 cases.
2.3 randomization After laparoscopic exploration and confirmation that the cases complied with the standards, they were included in the randomized groups in this study. SAS 9.2 was used to produce a serial number ranging from 0001 - 702 corresponding to the treatment allocation, which was reserved in the data center and research center.
2.4 Blinding Method: This research adopts an open design.
2.5 Research cycle: Estimated enrollment cycle: complete enrollment within 2 years. Follow-up period: the enrollment of the first case was the starting point for follow-up. And the enrollment of last case to the postoperative pathology report (generally 2 weeks after surgery) was the endpoint of follow-up for secondary outcomes. Three years after the last case was enrolled was the follow-up endpoint for the main outcomes.
Estimated time: 2023.12-2025.12 (complete enrollment) to 2028.12 (complete follow-up)
Study Objects All patients who meet the inclusion criteria and do not conform to the exclusion criteria are qualified for this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Procedure: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Indocyanine Green Tracer Using in Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Procedure: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
3D Laparoscopic Gastrectomy with Lymph Node Dissection
Procedure: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer
3-year disease free survival rate
Disease-free survival is calculated from the day of surgery to the day of recurrence or death
Time frame: 3 years
Operation time
Operation time
Time frame: 1 day
Total number of retrieved lymph nodes
Total number of retrieved lymph nodes
Time frame: 1 day
Noncompliance rate of lymph node dissection
Noncompliance rate of lymph node dissection
Time frame: 1 day
Relationship between fluorescent lymph nodes in group A and total number of lymph nodes in group A
Relationship between fluorescent lymph nodes in group A and total number of lymph nodes in group A
Time frame: 1 day
Relationship between fluorescent lymph nodes in Group A and positive lymph nodes in Group A (positive rate)
Relationship between fluorescent lymph nodes in Group A and positive lymph nodes in Group A (positive rate)
Time frame: 1 day
Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)
Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)
Time frame: 1 day
Relationship between non-fluorescent lymph nodes in Group A and negative lymph nodes in group A (negative rate)
Relationship between non-fluorescent lymph nodes in Group A and negative lymph nodes in group A (negative rate)
Time frame: 1 day
Relationship between nonfluorescent lymph nodes in Group A and positive lymph nodes in Group A (false negative rate)
Relationship between nonfluorescent lymph nodes in Group A and positive lymph nodes in Group A (false negative rate)
Time frame: 1 day
Relationship between fluorescent lymph nodes in group B and total number of lymph nodes in group B
Relationship between fluorescent lymph nodes in group B and total number of lymph nodes in group B
Time frame: 1 day
Relationship between fluorescent lymph nodes in Group B and positive lymph nodes in Group B (positive rate)
Relationship between fluorescent lymph nodes in Group B and positive lymph nodes in Group B (positive rate)
Time frame: 1 day
Relationship between fluorescent lymph nodes in Group B and negative lymph nodes in Group B (false positive rate)
Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)
Time frame: 1 day
Relationship between non-fluorescent lymph nodes in Group B and negative lymph nodes in group B (negative rate)
Relationship between non-fluorescent lymph nodes in Group B and negative lymph nodes in group B (negative rate)
Time frame: 1 day
Relationship between nonfluorescent lymph nodes in Group B and positive lymph nodes in Group B (false negative rate)
Relationship between nonfluorescent lymph nodes in Group B and positive lymph nodes in Group B (false negative rate)
Time frame: 1 day
Number of metastatic lymph nodes
Number of metastatic lymph nodes
Time frame: 1 day
Metastasis rate of lymph nodes
Metastasis rate of lymph nodes
Time frame: 1 day
Morbidity and mortality rates
Morbidity and mortality rates
Time frame: 30 day
3-year overall survival rate
3-year overall survival rate
Time frame: 3 years
3-year recurrence pattern
3-year recurrence pattern
Time frame: 3 years
Postoperative recovery course
Postoperative recovery course
Time frame: 30 days
Intraoperative situation
Intraoperative situation
Time frame: 30 days
Postoperative nutritional status
Postoperative nutritional status
Time frame: 3 years
Inflammatory and immune response
Inflammatory and immune response
Time frame: 30 days
Postoperative quality of life (measured by EQ-5D)
Postoperative quality of life (measured by EQ-5D)
Time frame: preoperative, postoperative 1 month and postoperative 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Jan 2026, 35 months after the start.
Of 73 non-industry phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 144. This study's planned 35 months is below that.
Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.